Achieving Optimal Visual Outcomes in Diabetic Eye Disease through a Multi-Disciplined Approach: The Importance of Early, Aggressive Therapy

Supported by an educational grants from Regeneron Pharmaceuticals, Inc and Optovue, Inc.

Jointly presented by the Univeristy of Nebraska Medical Center and ASiM.

OVERVIEW

Optimal management of patients with diabetic eye disease requires a multidisciplinary approach to disease management and treatment.  Through these archived case presentations and expert discussion among leaders in ophthalmology, endocrinology, and nephrology, this activity will provide attendees with the latest clinical data on the efficacy and safety of current and emerging ocular and systemic therapies. In addition, this activity will highlight the benefits of prompt diagnosis and early aggressive treatment of diabetic retinopathy and diabetic macular edema (DME).

Target Audience

This activity is designed for retina specialists in attendance. No prerequisites required.

Additional information
Goal: 

To provide participants with education that improves their ability to diagnose DME in its earliest stages and to provide optimal management through multidisciplinary approaches.

Accreditation Statement: 

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center and ASiM. The University of Nebraska Medical Center, Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

Confidentiality Disclaimer for CME Activity Participant: 

The University of Nebraska Medical Center, Center for Continuing Education, presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The University of Nebraska Medical Center, Center for Continuing Education assumes no liability for the information herein.

 

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance
Course opens: 
12/20/2016
Course expires: 
12/20/2017

Quan Dong Nguyen, MD, MSc (Course Director) 
Professor and McGaw Endowed Chair in Ophthalmology 
Inaugural Director and Chairman Emeritus, Stanley M. Truhlsen Eye Institute
Assistant Dean, Translational Research
University of Nebraska Medical Center
Omaha, Nebraska

Glenn M. Chertow, MD, MPH
Norman S. Coplon Satellite Healthcare Professor of Medicine
Chief, Division of Nephrology
Stanford University School of Medicine
Stanford, California

Diana V. Do, MD
Professor of Ophthalmology
Vice Chair for Education 
Director of the Carl Camras Center for Innovative Clinical Research
Director of the Ophthalmology Residency Training Program
Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center 
Omaha, Nebraska

Fredric B. Kraemer, MD
Professor of Medicine
Chief, Division of Endocrinology, Gerontology, and Metabolism
Stanford University School of Medicine
Stanford, California

Jennifer I. Lim, MD
Professor of Ophthalmology
Marion H. Schenk Esquire
Chair in Ophthalmology for Research in the Aging Eye
Director of the Retina Service
University of Illinois Eye and Ear Infirmary
Chicago, Illinois

David Sarraf, MD
Clinical Professor of Ophthalmology
Retinal Disorders and Ophthalmic Genetics Division 
Jules Stein Eye Institute, UCLA
Los Angeles, California

It is the policy of The University of Nebraska Medical Center to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a faculty or staff member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

Disclosures

Quan Dong Nguyen, MD, MSc – Advisory board: AbbVie Inc, Allergan Inc, Astellas Pharma Global Development Inc, Bausch & Lomb Incorporated, Bayer, Genentech Inc, Novartis, Ora Clinical, Regeneron Pharmaceuticals Inc, Santen Pharmaceuticals Co Ltd; Data Safety  Monitoring Board: Acucela Inc.

Diana V. Do, MD – Consultant: Allergan Inc, Genentech Inc, and Regeneron Pharmaceuticals Inc.

Jennifer I. Lim, MD – Advisory committee/board: AbbVie Inc; Consultant: Hospira/Pfizer Inc, ICON Bioscience Inc, and Lumenis; Industry funded research/investigator: Genentech Inc and Regeneron Pharmaceuticals Inc; Speakers' bureau/faculty/peer reviewer: Genentech Inc; AVTT Course supporter: Alcon; DMC for studies: Santen Pharmaceutical Co Ltd.

David Sarraf, MD – Industry funded research/investigator: Allergan Inc, Genentech Inc, Optovue Inc, Regeneron Pharmaceuticals Inc; Consultant: Genentech Inc, and Optovue; Speakers' bureau/faculty/peer reviewer: Optovue Inc.

Dr Kraemer and Dr Chertow, the planners, or other members at the University of Nebraska Medical Center, Center for Continuing Education and ASiM, who control content have no relevant financial relationships to disclose.

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Attendance

Learning Objectives

After attending this activity, the participant should be able to demonstrate the ability to:

  • Recognize strategies to manage diabetes, including diabetic nephropathy, as they relate to the overall benefit of treating diabetic retinopathy.
  • Review current evidence supporting early detection and early treatment for DME.
  • Assess evidence-based best practices regarding therapies used for early treatment of DME.
  • Evaluate strategies to effectively monitor dme during treatment, including assessment frequency and employment of novel imaging technology such as oct angiography, to improve/maintain visual acuity and prevent disease progression.
  • Develop treatment plans for DME considering disease progression and individual patient characteristics.

Accreditation Period

Course opens: 
12/20/2016
Course expires: 
12/20/2017
Please login or register to take this course.

Required Hardware/software

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, sound card and speakers, Adobe Acrobat Reader.